Digoxin-like immunoreactive substance in pregnancy

Antonio R. González, Stephanie Phelps, Emily B. Cochran, Baha M. Sibai

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Our aims were to determine the potential usefulness of digoxin-like immunoreactive substances in the prediction of preeclampsia, to study the relationship between fetal production of these substances and maternal serum levels, and to evaluate the association between digoxin-like immunoreactive substances and plasma volume findings in preeclamptic pregnancies. Serum digoxin-like immunoreactive substance concentrations were measured in normotensive and preeclamptic pregnant women and in umbilical artery and vein blood samples. None of the patients in the first trimester (n = 53) and 11 % of those in the second (n = 56) had detectable levels of this substance. However, 91% of the patients in the third trimester (n = 161) had positive results. The concentrations of digoxin-like immunoreactive substances in the preeclamptic group (n = 78) were significantly (p < 0.005) lower than those of third-trimester (n = 83) normotensive patients (0.22 ± 0.12 versus 0.32 ± 0.15 nglml). However, there were no significant differences between the two groups regarding digoxin-like immunoreactive substance concentrations when matched for gestational age (41 patients in each group). Digoxin-like immunoreactive substance concentrations in umbilical vessels were significantly higher (p < 0.001) than the corresponding maternal levels. Umbilical vessel digoxin-like immunoreactive substance levels demonstrated good correlation with fetal gestational age and birth weight in both normotensive and preeclamptic pregnancies. On the other hand, there was a poor (r = 0.02; p = 0.91) correlation between plasma volume findings and digoxin-like immunoreactive substance concentration. We conclude that the digoxin-like immunoreactive substance level may be of very little value in the prediction of preeclampsia. The presence of digoxin-like immunoreactive substance at greater concentrations in the umbilical cord blood samples suggests the possibility of the fetus as the source of this substance. Digoxin-like immunoreactive substances may not play a major role in plasma volume expansion during pregnancy.

Original languageEnglish (US)
Pages (from-to)660-664
Number of pages5
JournalAmerican Journal of Obstetrics and Gynecology
Volume157
Issue number3
DOIs
StatePublished - Jan 1 1987

Fingerprint

Pregnancy
Plasma Volume
Gestational Age
Umbilicus
Third Pregnancy Trimester
Pre-Eclampsia
digoxin-like factors
Mothers
Umbilical Veins
Umbilical Arteries
First Pregnancy Trimester
Serum
Fetal Blood
Birth Weight
Pregnant Women
Fetus

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology

Cite this

Digoxin-like immunoreactive substance in pregnancy. / González, Antonio R.; Phelps, Stephanie; Cochran, Emily B.; Sibai, Baha M.

In: American Journal of Obstetrics and Gynecology, Vol. 157, No. 3, 01.01.1987, p. 660-664.

Research output: Contribution to journalArticle

González, Antonio R. ; Phelps, Stephanie ; Cochran, Emily B. ; Sibai, Baha M. / Digoxin-like immunoreactive substance in pregnancy. In: American Journal of Obstetrics and Gynecology. 1987 ; Vol. 157, No. 3. pp. 660-664.
@article{54a4205f202f404b96b75d3290567d68,
title = "Digoxin-like immunoreactive substance in pregnancy",
abstract = "Our aims were to determine the potential usefulness of digoxin-like immunoreactive substances in the prediction of preeclampsia, to study the relationship between fetal production of these substances and maternal serum levels, and to evaluate the association between digoxin-like immunoreactive substances and plasma volume findings in preeclamptic pregnancies. Serum digoxin-like immunoreactive substance concentrations were measured in normotensive and preeclamptic pregnant women and in umbilical artery and vein blood samples. None of the patients in the first trimester (n = 53) and 11 {\%} of those in the second (n = 56) had detectable levels of this substance. However, 91{\%} of the patients in the third trimester (n = 161) had positive results. The concentrations of digoxin-like immunoreactive substances in the preeclamptic group (n = 78) were significantly (p < 0.005) lower than those of third-trimester (n = 83) normotensive patients (0.22 ± 0.12 versus 0.32 ± 0.15 nglml). However, there were no significant differences between the two groups regarding digoxin-like immunoreactive substance concentrations when matched for gestational age (41 patients in each group). Digoxin-like immunoreactive substance concentrations in umbilical vessels were significantly higher (p < 0.001) than the corresponding maternal levels. Umbilical vessel digoxin-like immunoreactive substance levels demonstrated good correlation with fetal gestational age and birth weight in both normotensive and preeclamptic pregnancies. On the other hand, there was a poor (r = 0.02; p = 0.91) correlation between plasma volume findings and digoxin-like immunoreactive substance concentration. We conclude that the digoxin-like immunoreactive substance level may be of very little value in the prediction of preeclampsia. The presence of digoxin-like immunoreactive substance at greater concentrations in the umbilical cord blood samples suggests the possibility of the fetus as the source of this substance. Digoxin-like immunoreactive substances may not play a major role in plasma volume expansion during pregnancy.",
author = "Gonz{\'a}lez, {Antonio R.} and Stephanie Phelps and Cochran, {Emily B.} and Sibai, {Baha M.}",
year = "1987",
month = "1",
day = "1",
doi = "10.1016/S0002-9378(87)80024-8",
language = "English (US)",
volume = "157",
pages = "660--664",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Digoxin-like immunoreactive substance in pregnancy

AU - González, Antonio R.

AU - Phelps, Stephanie

AU - Cochran, Emily B.

AU - Sibai, Baha M.

PY - 1987/1/1

Y1 - 1987/1/1

N2 - Our aims were to determine the potential usefulness of digoxin-like immunoreactive substances in the prediction of preeclampsia, to study the relationship between fetal production of these substances and maternal serum levels, and to evaluate the association between digoxin-like immunoreactive substances and plasma volume findings in preeclamptic pregnancies. Serum digoxin-like immunoreactive substance concentrations were measured in normotensive and preeclamptic pregnant women and in umbilical artery and vein blood samples. None of the patients in the first trimester (n = 53) and 11 % of those in the second (n = 56) had detectable levels of this substance. However, 91% of the patients in the third trimester (n = 161) had positive results. The concentrations of digoxin-like immunoreactive substances in the preeclamptic group (n = 78) were significantly (p < 0.005) lower than those of third-trimester (n = 83) normotensive patients (0.22 ± 0.12 versus 0.32 ± 0.15 nglml). However, there were no significant differences between the two groups regarding digoxin-like immunoreactive substance concentrations when matched for gestational age (41 patients in each group). Digoxin-like immunoreactive substance concentrations in umbilical vessels were significantly higher (p < 0.001) than the corresponding maternal levels. Umbilical vessel digoxin-like immunoreactive substance levels demonstrated good correlation with fetal gestational age and birth weight in both normotensive and preeclamptic pregnancies. On the other hand, there was a poor (r = 0.02; p = 0.91) correlation between plasma volume findings and digoxin-like immunoreactive substance concentration. We conclude that the digoxin-like immunoreactive substance level may be of very little value in the prediction of preeclampsia. The presence of digoxin-like immunoreactive substance at greater concentrations in the umbilical cord blood samples suggests the possibility of the fetus as the source of this substance. Digoxin-like immunoreactive substances may not play a major role in plasma volume expansion during pregnancy.

AB - Our aims were to determine the potential usefulness of digoxin-like immunoreactive substances in the prediction of preeclampsia, to study the relationship between fetal production of these substances and maternal serum levels, and to evaluate the association between digoxin-like immunoreactive substances and plasma volume findings in preeclamptic pregnancies. Serum digoxin-like immunoreactive substance concentrations were measured in normotensive and preeclamptic pregnant women and in umbilical artery and vein blood samples. None of the patients in the first trimester (n = 53) and 11 % of those in the second (n = 56) had detectable levels of this substance. However, 91% of the patients in the third trimester (n = 161) had positive results. The concentrations of digoxin-like immunoreactive substances in the preeclamptic group (n = 78) were significantly (p < 0.005) lower than those of third-trimester (n = 83) normotensive patients (0.22 ± 0.12 versus 0.32 ± 0.15 nglml). However, there were no significant differences between the two groups regarding digoxin-like immunoreactive substance concentrations when matched for gestational age (41 patients in each group). Digoxin-like immunoreactive substance concentrations in umbilical vessels were significantly higher (p < 0.001) than the corresponding maternal levels. Umbilical vessel digoxin-like immunoreactive substance levels demonstrated good correlation with fetal gestational age and birth weight in both normotensive and preeclamptic pregnancies. On the other hand, there was a poor (r = 0.02; p = 0.91) correlation between plasma volume findings and digoxin-like immunoreactive substance concentration. We conclude that the digoxin-like immunoreactive substance level may be of very little value in the prediction of preeclampsia. The presence of digoxin-like immunoreactive substance at greater concentrations in the umbilical cord blood samples suggests the possibility of the fetus as the source of this substance. Digoxin-like immunoreactive substances may not play a major role in plasma volume expansion during pregnancy.

UR - http://www.scopus.com/inward/record.url?scp=0023197270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023197270&partnerID=8YFLogxK

U2 - 10.1016/S0002-9378(87)80024-8

DO - 10.1016/S0002-9378(87)80024-8

M3 - Article

VL - 157

SP - 660

EP - 664

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 3

ER -